Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2013

Study Completion Date

December 31, 2013

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

gadobenate dimeglumine (MultiHance)

The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.

Trial Locations (1)

21287

The Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

collaborator

Bracco Diagnostics, Inc

INDUSTRY